Once weekly fluconazole for antifungal prophylaxis post-liver transplantation

HPB (Oxford). 2013 Jul;15(7):541-7. doi: 10.1111/hpb.12006. Epub 2012 Nov 22.

Abstract

Background: Invasive fungal infections (IFI) remain a significant cause of morbidity and mortality in orthotopic liver transplantation (OLT) recipients. In this retrospective study, the outcomes of a protocol using once weekly fluconazole for 3 months after OLT in low- and high-risk patients were reviewed.

Methods: In total, 221 OLTs were evaluated in the 3-year period after institution of the new protocol to determine the incidence of IFI within 6 months post-OLT.

Results: In this cohort, 11 IFIs developed during the 6-month post-transplant period, with the majority being non-albicans Candida. High-risk patients had a greater rate of IFI (16.7% versus 3.4%, P = 0.038) and a significantly longer intensive unit care (ICU) and hospital lengths of stay compared with low-risk patients. Patient and graft survival were similar between the groups. Our patient population appeared to be at low risk for IFI, with 92% of the entire cohort considered low risk.

Discussion: Given the low incidence of IFI in the low-risk group and the possibility of such protocol selecting out for fluconazole-resistant fungi, the use of weekly fluconazole for 3 months may not be justifiable in low-risk OLT recipients. Given the increased resource utilization observed with IFI, further examination of a more intensive prophylactic strategy in high-risk patients may be warranted.

MeSH terms

  • Adult
  • Antifungal Agents / administration & dosage*
  • Drug Administration Schedule
  • Female
  • Fluconazole / administration & dosage*
  • Graft Survival
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Incidence
  • Intensive Care Units
  • Length of Stay
  • Liver Transplantation / adverse effects*
  • Liver Transplantation / mortality
  • Logistic Models
  • Male
  • Middle Aged
  • Missouri / epidemiology
  • Multivariate Analysis
  • Mycoses / diagnosis
  • Mycoses / microbiology
  • Mycoses / mortality
  • Mycoses / prevention & control*
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Immunosuppressive Agents
  • Fluconazole